Delcath Q2 revenue $29.1M, up 20% YoY; raises FY 2026 revenue guidance to $104-108M

DELCATH SYSTEMS, INC.

Total revenue $29.1M (Q2 2026) vs $24.2M (Q2 2025); HEPZATO KIT $27.1M, CHEMOSAT $2.0M.
Net income $2.7M (flat YoY); non-GAAP adjusted EBITDA $7.6M vs $9.8M prior year.
Cash and investments $95.9M, no debt as of June 30, 2026.
FY 2026 revenue guidance raised to $104-108M (≥28% HEPZATO volume growth); gross margins 86-89%.
31 active treatment centers; HEPZATO volume grew ~30% YoY in Q2.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.